STD & STI questions, answered straight.

Three main routes: order an at-home kit online and mail in a self-collected sample; walk into a private lab (Quest, Labcorp and partners) for results in 1–3 days with no appointment; or visit a public health department or community clinic for free or sliding-scale testing. Pick your state above to see options near you.

Self-pay private testing runs about $24, $200 depending on the panel; at-home kits are roughly $45, $300. Public health clinics and Title X centers test for free or on a sliding scale, and most ACA insurance plans cover recommended screening with no out-of-pocket cost.

Yes. Health departments, Title X family-planning clinics and federally funded community health centers offer free or low-cost confidential testing nationwide, regardless of insurance or ability to pay. Choose your state to find them.

At-home kits use the same CLIA-certified lab methods (NAAT) as in-clinic tests, so they're highly accurate when you follow the collection instructions. If a result is positive, the service connects you with a clinician for treatment.

A standard panel covers chlamydia, gonorrhea, syphilis and HIV; comprehensive panels add hepatitis B & C, herpes, and trichomoniasis. What you need depends on your exposures, use the symptom checker or compare-options tool to narrow it down.

It applies the CDC's published STI screening recommendations to your answers. For example: the CDC advises everyone 13–64 get an HIV test at least once; every adult 18+ get screened once for hepatitis B and hepatitis C; sexually active people with a cervix under 25 get yearly chlamydia and gonorrhea tests; and men who have sex with men get tested at every site of exposure at least yearly. It's a transparent rules engine, not a black box, every recommendation shows its reason.

Because chlamydia and gonorrhea infect the throat and rectum, and a standard urine test misses those infections. The CDC recommends testing at every site of exposure: a throat swab if you have oral sex, a rectal swab if you have receptive anal sex. Many people are told they're 'negative' on a urine test while carrying an untreated throat or rectal infection, so this is one of the most important questions.

Probably not, if you have no symptoms. The CDC does not recommend routine herpes (HSV) blood testing for people without symptoms: the antibody test can't tell where the infection is and produces frequent false positives, causing needless anxiety. If you have a sore or blister, the right test is a swab of that lesion, not a blood test. Talk to a provider about testing if a partner has genital herpes.

For most sexually active people, once a year is the baseline. If you have multiple or anonymous partners, are a man who has sex with men at higher risk, or are on HIV PrEP, the CDC recommends every 3–6 months. Test again about 3 months after any treatment, and get tested promptly, don't wait for your annual visit, if you develop symptoms or learn a partner has an STI.

It's completely private: every answer stays in your browser and is never sent, saved, or shared. And no, it can't diagnose you: it's an educational tool that turns CDC screening guidance into a personalized checklist. Only a clinician and an actual test can diagnose an infection. Bring your panel to a provider or an at-home testing service.

Which test you need is only half of it, timing is the other half. Every infection has a window period, the gap between exposure and when a test can reliably detect it, and testing inside that window can hand you a falsely reassuring negative. For chlamydia and gonorrhea, a NAAT is generally reliable about two weeks after exposure. HIV depends on the test: a nucleic-acid test detects it roughly 10–33 days out, a lab antigen/antibody test about 18–45 days, and a rapid antibody test about 23–90 days. Syphilis antibodies also take time to rise. If you test early and it's negative, repeat it once the window has fully passed.

Self-pay is more affordable than most expect: à la carte single tests start around $24–$49, a full 10-test lab panel runs from $139, and at-home kits range from about $99 to $209. Free or sliding-scale testing is available at public clinics.

Yes. Self-pay private labs, at-home kits and public clinics don't bill insurance, so nothing appears on your Explanation of Benefits or in your primary-care record. See our guide to anonymous and private testing for details.

You provide a sample, a blood draw, urine sample, or swab depending on the test, either at a lab or by self-collecting an at-home kit. Results post to a secure online portal, typically in 1–2 days for a lab and a few days for a mail-in kit, with a clinician available if anything is positive.

No. Private lab services and at-home kits let you order online with no referral and no appointment: you walk into a partner lab whenever it suits you, or collect at home. Only doctor/telehealth visits and some public clinics need an appointment.

Yes, and it's the norm. Most people with chlamydia have no symptoms at all, so you can carry it and pass it on while feeling completely fine. That's why testing after a new partner matters more than waiting to feel unwell.

When symptoms appear, usually 1–3 weeks after exposure, they can include unusual discharge, a burning feeling when you urinate, pain during sex, or bleeding between periods. Many people never get any, and throat or rectal infections are almost always symptom-free.

A chlamydia test is generally reliable about 1–2 weeks after exposure. Testing earlier can miss a recent infection: if an early test is negative but you had a real exposure, repeat it after two weeks.

Often, yes. Because most chlamydia is silent, the CDC recommends yearly screening for all sexually active women under 25 and for anyone with new or multiple partners. No symptoms doesn't mean no infection.

It's easily cured, but untreated it can spread. In people with a uterus it can cause pelvic inflammatory disease, which can lead to chronic pain, ectopic pregnancy, and infertility. Catching it early with a simple test avoids all of that.

You often can't from symptoms alone: that's the honest answer, and it matters. Classic patterns exist: yeast tends to cause thick, white, cottage-cheese-like discharge with intense itching and no odor; BV causes thin, gray discharge with a fishy smell; trichomoniasis (an STI) causes frothy yellow-green discharge with odor and itching. But they overlap heavily, and trichomoniasis in particular mimics BV and yeast. Only a provider's exam or a test can tell them apart reliably.

No, neither bacterial vaginosis nor a yeast infection is a sexually transmitted infection. Both come from a change in the natural balance of bacteria or yeast in the vagina, and you can get them without any sexual contact. That said, their symptoms overlap with real STIs like trichomoniasis, so it's worth confirming the cause rather than assuming.

Because trichomoniasis is a sexually transmitted infection, and it's the one most often mistaken for BV or a yeast infection. If it's trich, treating yourself for yeast won't work, your partner needs treatment too, and it should prompt testing for other STIs. Trich is very common and easily cured with antibiotics once it's correctly identified, which is exactly why testing rather than guessing matters.

Only if you're sure it's yeast, and studies show most people who self-diagnose yeast are wrong a lot of the time. If an over-the-counter antifungal doesn't clear things up in a few days, if you have a fishy odor or greenish discharge, if there's burning when you pee or bleeding, or if you've had a new partner, see a provider and get tested rather than repeating treatment.

Soon, if you have a new or unusual discharge, a fishy or foul odor, itching or burning that doesn't settle, pain during sex, bleeding between periods, or pelvic or lower-belly pain, or if you've had a recent new partner. These can signal an STI or an infection that needs prescription treatment, and some (like untreated chlamydia or gonorrhea) can affect fertility if ignored.

They can look alike at first, but there are tells. A pimple or ingrown hair is usually a single tender bump with a white pus head or a hair trapped under it, and it clears in a few days. Herpes tends to be a cluster of small, painful blisters that often start with tingling, break open into shallow sores, and recur over time. If a bump is painful, blisters, appears in a cluster, or doesn't heal within a week or so, get it checked, only a clinician (sometimes with a swab) can tell for sure.

Yes, this is the most important one to know. A syphilis sore (chancre) is classically a single, firm, painless open sore that shows up around three weeks after exposure and heals on its own in a few weeks. Because it's painless and goes away, it's easy to ignore, but the infection stays in your body and progresses if untreated. Any painless genital ulcer should be evaluated and tested for syphilis promptly.

Both are usually painless. Genital warts (HPV) are flesh-colored or gray, soft, and can be flat or cauliflower-like, sometimes clustering and growing over weeks. Molluscum contagiosum bumps are firm, pearly or flesh-colored domes with a tiny dimple in the center. A clinician can usually tell them apart by sight, and both are manageable.

Probably not. Neat rows of tiny, smooth, dome-shaped bumps around the head of the penis are pearly penile papules, and scattered pale or yellowish dots on the shaft or vulva are Fordyce spots. Both are completely normal, non-infectious anatomy present in a large share of people: not an STI, not contagious, and nothing to treat. If they're new, changing, or you're unsure, a clinician can confirm in seconds.

No. Squeezing or picking at a genital bump can spread infection, cause scarring, or make a diagnosis harder. Don't apply over-the-counter wart treatments to the genitals either, they're not made for that skin. The safe move for any new, painful, open, or persistent genital bump or sore is to have a clinician look at it.

No. Genital bumps and sores have a lot of look-alikes, and even experienced clinicians often confirm with a swab or blood test. This tool shows you which causes fit the pattern you describe and how they differ, it can't tell you which one you have. Use it to understand what you're seeing and how urgently to act, then see a provider.

In most of the country, yes. Every U.S. state allows minors to consent to their own STI testing and treatment; states differ only on the minimum age: many allow a minor of any age, while others set a floor such as 12 or 14. Pick your state above for its specific rule. This is separate from confidentiality (see below).

It can. When you bill insurance, the insurer may mail an Explanation of Benefits (EOB) to the policyholder, which could be a parent or spouse. Under HIPAA (45 CFR 164.522) you can ask your insurer in writing to send communications confidentially, and some states add extra protections. To keep a test fully off insurance, use a self-pay private lab, an at-home kit, or a public health clinic.

Test without involving insurance or your regular doctor: pay out of pocket at a private lab, order an at-home kit, or visit a public health clinic, none of these send an EOB to a policyholder. Many health departments offer free or low-cost testing, and some sites offer anonymous HIV testing where your name is never attached to the result.

No, they're two different things. Consent is whether a minor can say yes to testing on their own (allowed in every state). Confidentiality is whether the results stay private, which can be affected by insurance EOBs even when a minor consented. If privacy matters, a self-pay or clinic option avoids the insurance trail.

EPT lets a provider give you medication (or a prescription) to pass to your sexual partner if you test positive for chlamydia or gonorrhea, so your partner can be treated without their own separate exam. Most states permit it. It's a fast way to stop reinfection and protect partners.

No. This is general information compiled from public sources (the Guttmacher Institute, HIPAA regulations, and CDC guidance) and can change. For your specific situation, confirm with a clinic, a health department, or a qualified professional.

Rarely, and mostly only for HIV. Most STD testing is confidential (your identity is recorded but legally protected), not anonymous (no identity collected at all). Truly anonymous testing is limited to HIV at certain public-health sites that issue a code instead of a name, and to at-home HIV self-tests. For full panels, the realistic and completely achievable goal is private testing, nothing on your insurance and nothing with your regular doctor.

No. Routine employment background checks look at criminal history, identity and work history, not medical records. STD test results are protected health information and don't appear on a standard background check, and they aren't shared with employers or schools.

If you bill insurance, an Explanation of Benefits may be mailed to the policyholder and the result enters your medical record. To keep it private, self-pay at a private lab, use an at-home kit, or visit a public clinic, none bill insurance. Under HIPAA you can also ask your insurer to send communications confidentially.

Yes, for certain infections. HIV, syphilis, gonorrhea, chlamydia and a few others are 'notifiable', the lab (not you) reports positive cases to public health for disease tracking and partner-notification programs. This applies wherever you test. Reporting is confidential and isn't shared with employers, schools, or used against you.

You can pay privately, which is what matters. Cash at a public clinic, an HSA/FSA card, or a regular card for a self-pay test all keep the test off your insurance. The charge on a statement shows the lab or retailer's name, not the test you ordered.

In most states, yes: minors can consent to confidential STI testing on their own, though the age and rules vary by state (use the lookup above). Even where a minor can consent, an insurance EOB sent to a parent can break confidentiality, so self-pay or a public clinic is often the most private route for a teen.

Anonymous partner-notification services send a text or email telling past partners to get tested without naming you. It's the responsible step after a positive result and keeps your identity private.

Two things top the list. If you're HIV-negative, PrEP lowers your risk from sex by about 99% when taken as prescribed (now available as a daily pill, a shot every two months, or a twice-yearly injection). And if a partner is living with HIV, an undetectable viral load on treatment means they can't transmit it at all: 'Undetectable = Untransmittable' (U=U), effectively zero risk. Condoms and PEP (within 72 hours of an exposure) add further protection. PrEP is HIV-only, so pair it with condoms or doxy-PEP for other STIs.

Very well for the fluid-borne infections and pregnancy, and partially for skin-to-skin ones. Used consistently and correctly, external condoms are about 98% effective against pregnancy (around 87% with typical use) and sharply cut HIV, chlamydia, gonorrhea, and syphilis. Because they can't cover all skin, protection against herpes and HPV is partial. Condoms are the only single method that reduces both STIs and pregnancy, which is why they pair well with everything else.

Doxy-PEP is a single 200 mg dose of doxycycline taken within 72 hours after sex to prevent bacterial STIs. In trials it cut infections by about 65% on average: roughly 74–88% for chlamydia and syphilis and 55–57% for gonorrhea (lower, and affected by antibiotic resistance). It does nothing for HIV or viral STIs, and the CDC recommends it for gay and bisexual men and transgender women who've had a bacterial STI in the past year.

Yes, for two big ones. The HPV vaccine prevents about 90% of the HPV types that cause genital warts and several cancers, and the hepatitis B vaccine is over 90% effective, both work best given before exposure. There's no vaccine yet for HIV, herpes, chlamydia, or gonorrhea. Vaccination is one of the most durable forms of prevention because the protection lasts for years.

There isn't one, that's the honest answer. Each method has gaps: PrEP is HIV-only, condoms can't cover all skin, doxy-PEP is bacterial-only, vaccines cover specific viruses. The strongest protection comes from layering: condoms plus PrEP if you're at HIV risk, the HPV and hepatitis B vaccines, doxy-PEP if you qualify, and routine testing so anything is caught early. Combining a few methods covers far more than any one alone.

It uses the HIRI-MSM (HIV Incidence Risk Index for men who have sex with men), a screening score validated in U.S. studies for gay and bisexual men, other men who have sex with men, and transgender women. If you don't fall into those groups, the score won't be accurate, but PrEP may still be right for you. The CDC recommends PrEP for anyone with an HIV-positive partner, a recent bacterial STI, condomless sex with partners of unknown status, or anyone who simply requests it. Talk to a provider.

The HIRI-MSM runs from 0 to 47. A score of 10 or higher is the validated threshold that flags increased HIV risk, at that level the CDC and the tool's authors say PrEP should be discussed and offered. A score of 10 was associated with roughly a 2% chance of acquiring HIV per year in the original studies, and a score of 25 or more with about 7% per year. A score below 10 does not mean you can't or shouldn't take PrEP.

No. The 2021 CDC clinical practice guideline is explicit: PrEP should be prescribed to anyone who asks for it, even without a specific risk factor. A below-threshold score means this particular screen didn't flag elevated risk: it does not rule out PrEP, and it doesn't mean your risk is zero. Your own judgment about your situation matters, and a provider can help you decide.

PrEP (pre-exposure prophylaxis) is medicine taken by HIV-negative people to prevent HIV. Taken as prescribed, oral PrEP reduces the risk of getting HIV from sex by about 99%. It comes as a daily pill (Truvada or Descovy) or a long-acting injection (Apretude / cabotegravir) given every two months. PrEP only prevents HIV, not other STIs, so it's paired with condoms and regular testing.

PrEP is prescription-only. A primary-care provider, sexual-health or HIV clinic, or telehealth service can prescribe it after a quick HIV test and a few labs, with follow-up every three months. Because the USPSTF gives PrEP its top (Grade A) rating, most insurance plans must cover it, including the medication and the required visits and labs, with no out-of-pocket cost. If you're uninsured, free 340B telehealth services, manufacturer assistance programs, and state PrEP funds still get most people to $0 (the federal Ready, Set, PrEP program ended in 2025). See our PrEP cost guide for the details.

Yes. This calculator runs entirely in your browser. Your answers are never sent to a server, saved, or shared, refresh the page and they're gone. We can't see them and neither can anyone else.

The CDC's 2024 guidelines recommend counseling on doxy-PEP for gay and bisexual men and other men who have sex with men (MSM) and for transgender women who have had a bacterial STI, chlamydia, gonorrhea, or syphilis, diagnosed in the past 12 months. For these groups, providers should offer a prescription through shared decision-making.

Not as a routine recommendation. The CDC found insufficient evidence of benefit for cisgender women, cisgender heterosexual men, and transgender men, a key trial in cisgender women did not show a protective effect. If you're in one of these groups, talk to your provider about other prevention: condoms, vaccination (HPV, hepatitis, mpox), regular testing, and HIV PrEP.

The regimen is a single 200 mg dose of doxycycline taken as soon as possible, and ideally within 72 hours, after oral, vaginal, or anal sex, not to exceed 200 mg in any 24-hour period. It is taken after sex (post-exposure), not daily.

In three large randomized trials, 200 mg of doxycycline within 72 hours of sex reduced syphilis and chlamydia infections by more than 70% and gonorrhea by roughly 50%. Gonorrhea protection is lower and varies with local antibiotic resistance.

No. Doxy-PEP only lowers the risk of three bacterial STIs. It does not prevent HIV or other infections, and it is meant to sit alongside condoms, vaccination, HIV PrEP, and routine STI testing every 3–6 months, not replace them.

Doxy-PEP is prescription-only. Ask a primary-care provider, a sexual-health or STI clinic, an HIV/PrEP clinic, or a telehealth sexual-health service. This tool is informational and cannot prescribe it, bring your result to that conversation.

Three. HPV, the virus behind most cervical and several other cancers plus genital warts, is prevented by the HPV vaccine. Hepatitis A and hepatitis B, both spread through sex, each have a safe, long-standing vaccine (and a combined shot covers both). And mpox, which spread largely through sexual networks in the 2022 outbreak, is prevented by the two-dose JYNNEOS vaccine. There's no vaccine yet for chlamydia, gonorrhea, syphilis, herpes, or HIV: for those, testing and prevention like PrEP are the tools.

Not necessarily. HPV vaccination is routinely recommended through age 26 for anyone not already caught up. For adults 27 through 45, the CDC recommends 'shared clinical decision-making': meaning it isn't automatic, but you and your provider can decide it's worthwhile based on your situation, for example if you have new or multiple partners. After 45 it isn't recommended.

Yes. In 2022 the CDC began recommending hepatitis B vaccination for all adults aged 19–59, regardless of risk: it's that safe and that effective, and it removed the old need to disclose risk factors to qualify. Adults 60 and older can still get it, and it's specifically recommended for them if they have risk factors like multiple partners, injection drug use, HIV, or diabetes.

The CDC recommends the two-dose JYNNEOS vaccine for gay and bisexual men, other men who have sex with men, and transgender people who in the past 6 months had a new STI diagnosis, more than one sex partner, or sex at a commercial venue or in connection with a large event in an area with mpox, and for their sexual partners. It's given as two shots 28 days apart.

Many people got hepatitis B as infants (it's been routine since the 1990s) and some got HPV as pre-teens. Check your immunization records, your state's immunization registry, or ask your provider or pharmacist, they can look it up and test your hepatitis B immunity if it's unclear. You don't need to repeat a completed series.

Completely. This tool runs entirely in your browser: your answers are never sent to a server, saved, or shared. It's educational and can't diagnose you or order a vaccine; a clinician or pharmacist does that. Bring your checklist to them.

Two things are time-sensitive, so act on them first. If there's any chance of HIV exposure, PEP (post-exposure prophylaxis) can prevent infection but only if started within 72 hours, the sooner the better. If pregnancy is possible, emergency contraception works up to 5 days after, and sooner is more effective. After those, plan to test for STIs at the right time and take a pregnancy test a few weeks later. This tool sorts these for you by how long ago it happened.

Up to 5 days, but effectiveness drops the longer you wait. Levonorgestrel pills (Plan B and generics) are available over the counter with no age limit and work best within 3 days. Ella (ulipristal, prescription) works up to 5 days and is equally effective across that window. The copper IUD, placed by a provider within 5 days, is the most effective option of all, over 99%, and, unlike the pills, its effectiveness isn't reduced at higher body weight.

It can be less reliable. Levonorgestrel (Plan B) is less effective at a BMI over 25 and may not work at a BMI of 30 or more; ella can be less effective at higher body weight too (around 195 lb / a BMI of 35). The copper IUD is not affected by weight, so it's the preferred emergency option if you weigh more and strongly want to avoid pregnancy. A provider or pharmacist can help you choose.

Not right away, tests need time to become reliable. Different infections have different window periods: HIV and syphilis around a few weeks, chlamydia and gonorrhea about 1–2 weeks. Use our test-window calculator to time it, and remember that most STIs cause no symptoms, so test whether or not you feel anything.

Correct, they're completely different. Emergency contraception (Plan B, ella) prevents pregnancy from starting and does nothing if you're already pregnant; it's not the same as the abortion pill (mifepristone/misoprostol), which ends an established pregnancy. EC is safe, and the levonorgestrel type is sold right on the pharmacy shelf.

Most breaks trace to something avoidable rather than a defective condom: putting it on after genital contact already started, using an oil-based product like lotion, baby oil, or petroleum jelly (oil degrades latex: use a water- or silicone-based lube instead), reusing a condom, or not pinching the air out of the tip before unrolling, since trapped air is a common cause of breakage. If breaks keep happening, fit is usually the culprit: one that's too tight or too loose fails more easily, so it's worth finding a size that sits comfortably.

A chlamydia test is quick and painless: no exam, no needles. You give a urine sample (holding urine for at least an hour beforehand improves sensitivity), or a swab is taken from the vagina, rectum, or throat depending on your exposures. You can often self-collect the swab. Options include ordering online at a private lab and walking in with no appointment, visiting a health department or sexual health clinic, or using an at-home kit you collect and mail yourself. Results come back in 1–3 days for most labs, a few days more for mailed kits. If you've had anal or oral sex and haven't specifically requested rectal or throat testing, ask for those separately, genital testing alone will miss infections at those sites.

Wait at least 1–2 weeks after a possible exposure before testing. Chlamydia trachomatis needs time to replicate inside your cells to reach the concentrations that NAAT can reliably detect, and testing in the first few days carries a meaningful risk of a false-negative result. Two weeks is the threshold cited in most clinical guidance. If you test at one week and get a negative result, but you had a known exposure or have symptoms, re-test at the 2-week mark to confirm. There is no benefit to testing on the same day as exposure.

Yes, at-home chlamydia testing is accurate and widely available. At-home kits use the same NAAT technology as clinic-based labs: you self-collect a urine sample and/or vaginal swab according to the kit instructions, seal and mail the sample to a CLIA-certified laboratory, and receive confidential results online, typically within 2–5 days of the lab receiving your sample. If a result is positive, the testing service connects you with a licensed clinician who can prescribe treatment. At-home testing is a good option if cost, stigma, distance from a clinic, or scheduling is a barrier, the accuracy is comparable to in-person testing when samples are collected correctly.

Self-pay at a private lab (Quest, LabCorp, and similar) runs approximately $24: $80 for chlamydia alone, and combination STI panels that include gonorrhea run slightly more. At-home kits cost approximately $45, $150 depending on how many conditions are tested. For free or low-cost options, local health departments, Title X family planning clinics, community health centers, and Planned Parenthood locations offer free or sliding-scale testing, call ahead to confirm they test for chlamydia specifically. If you have ACA-compliant insurance, recommended preventive screening is covered with no out-of-pocket cost; ask the clinic to bill it as preventive care.

Yes, chlamydia is completely curable with antibiotics. The preferred treatment is doxycycline 100 mg twice daily for 7 days; a single 1g dose of azithromycin is an alternative when the full course isn't practical. No clinically significant antibiotic resistance exists for chlamydia: unlike gonorrhea, where resistance is a serious and growing problem. You are generally considered non-contagious 7 days after starting treatment, but you should avoid sex for all 7 days of the doxycycline course and until all of your recent partners have completed their own treatment. Having it once does not make you immune, you can be re-infected the same day treatment ends if you have sex with someone who still has it.

Indefinitely, and this is what makes chlamydia uniquely dangerous. Because most infections cause no symptoms, and because symptoms that do appear are often mild and easily confused with other things (a UTI, normal discharge variation, mild irritation), people can carry and transmit chlamydia for months or even years without suspecting anything is wrong. During that entire time, in women, the infection may be slowly progressing into the upper reproductive tract and accumulating scarring damage. There is no biological clock that clears it on its own, chlamydia does not resolve without treatment. Routine testing is the only way to catch silent infection before it causes harm.

No. Chlamydia trachomatis infects columnar epithelial cells found in the genital tract, rectum, and throat: it is transmitted through sexual contact involving these sites, not through saliva or casual oral contact. Kissing, hugging, sharing drinks or food, or using the same toilet seat does not transmit chlamydia. The bacterium cannot survive outside of human cells, so environmental transmission is not possible. Throat chlamydia is spread through oral sex, not kissing.

No: hormonal contraception of any kind (pills, the patch, the ring, the shot, implants, or hormonal IUDs) prevents pregnancy but provides zero protection against chlamydia or any other sexually transmitted infection. Only barrier methods, condoms used correctly and consistently, reduce chlamydia transmission risk, by approximately 60–70%. If you are on hormonal birth control and sexually active with new or multiple partners, you still need regular STI screening and should use condoms with partners whose STI status is unknown.

Almost always, yes, especially if the infection was caught and treated before it progressed to complications. Chlamydia threatens fertility only when it has advanced to pelvic inflammatory disease (PID) with fallopian tube scarring, and even then, fertility is reduced rather than eliminated in most cases. One episode of PID raises infertility risk by roughly 12%; multiple episodes raise it further. The key is testing early, before PID develops, which is exactly what annual screening for women under 25 is designed to accomplish. If you have been treated for chlamydia and are having difficulty conceiving, a conversation with a reproductive specialist about tubal patency is worthwhile.

You do not need a routine "test-of-cure" (confirming the infection is gone) after completing treatment, with one important exception: during pregnancy, a test-of-cure is recommended about 3 weeks after treatment to confirm clearance, because of the risk to the newborn. For everyone else, the treatment is reliable enough that a post-treatment test is not routinely indicated: and NAAT can remain positive for several weeks due to residual bacterial DNA even after successful treatment, which can create confusion. What the CDC does recommend is re-testing 3 months after treatment, not to check that treatment worked, but to catch new infections, because re-infection from an untreated partner in the 3-month window is common.

Yes: not because the treatment failed, but because chlamydia provides no lasting immunity and re-infection is common. The most frequent scenario is that an infected partner was not tested or did not complete treatment, and the infection passed back and forth. This is why treating all recent partners and avoiding sex for 7 days after treatment begins (and until partners are treated) is the essential companion to your own treatment. If you test positive again within a few months of treatment, the most likely explanation is re-infection, not treatment failure. Antibiotic resistance in chlamydia is extremely rare; re-exposure is the overwhelming cause of recurrent positive tests.

Chlamydia and gonorrhea are both bacterial STIs that often have no symptoms, infect similar anatomic sites (cervix, urethra, rectum, throat), and can cause PID and infertility, which is why they are frequently tested together. The key differences: chlamydia is caused by Chlamydia trachomatis (an intracellular bacterium), while gonorrhea is caused by Neisseria gonorrhoeae (a conventional extracellular bacterium). Gonorrhea causes symptoms more often when they do occur, particularly discharge that tends to be more pronounced and purulent. Most importantly, gonorrhea has developed extensive antibiotic resistance, leaving only one reliably effective treatment regimen (ceftriaxone injection) as of 2024; chlamydia remains curable with oral doxycycline. Co-infection with both is common, roughly 30–50% of people with gonorrhea also test positive for chlamydia.

Rarely, but yes. The primary male complication is epididymitis: inflammation and scarring of the epididymis, the tube that stores and transports sperm from the testicle. Severe or recurrent epididymitis can damage sperm maturation and, in rare cases, cause obstruction that reduces fertility. Orchitis (testicular inflammation) can also occur. The male fertility consequences of chlamydia are far less common and less well-documented than the female equivalents, partly because men are more likely to have symptomatic epididymitis (pain prompts treatment before severe scarring develops) and partly because male fertility is harder to track epidemiologically. Prompt treatment of symptomatic epididymitis essentially eliminates the fertility risk.

Pelvic inflammatory disease (PID) is an infection of the upper female reproductive tract: the uterine lining (endometritis), fallopian tubes (salpingitis), ovaries (oophoritis), and surrounding pelvic tissue. Chlamydia causes it by ascending from the cervix upward into these structures, triggering an inflammatory response. The inflammation itself damages the delicate tissue of the fallopian tubes: not by destroying the tube outright, but by causing scarring and adhesions that narrow or block it. The insidious part is that roughly 70% of PID is subclinical: no fever, no severe pain, no clear signal that something is wrong inside. This silent scarring is exactly what drives the long-term fertility consequences: a woman may discover she has tubal factor infertility years later, with no memory of ever feeling sick.

Yes. A newborn can contract chlamydia during vaginal delivery if the mother has an untreated infection at the time of birth. The two main presentations in newborns are conjunctivitis (ophthalmia neonatorum), a sticky, purulent eye discharge appearing in the first week of life, and pneumonia, appearing between weeks 2 and 12 of life. Chlamydial pneumonia in infants is distinctive: it causes a repetitive, staccato cough without fever and shows diffuse infiltrates on chest X-ray. It is the most common cause of afebrile pneumonia in infants 1–3 months of age. Both conditions are treated with azithromycin and are entirely preventable through prenatal screening and treatment. This is why chlamydia testing at the first prenatal visit is a standard part of prenatal care.

Gonorrhea is diagnosed with a NAAT (nucleic acid amplification test), which detects bacterial DNA from a sample collected at any infected site. For genital infection, you give a urine sample or a vaginal, cervical or urethral swab, you can often self-collect. If you've had receptive anal or oral sex, site-specific rectal and throat swabs are the only way to detect infections at those sites; a urine test will miss them entirely. Gonorrhea and chlamydia are almost always run on the same sample. Most private labs and at-home kits offer NAAT testing with results in 1–3 days, and no appointment is required at most direct-access labs.

Yes: gonorrhea is curable, but only with the right antibiotic given at the right dose. The CDC-recommended treatment is a single 500 mg intramuscular injection of ceftriaxone (1 g if body weight is 150 kg or more). When this is administered correctly, it reliably clears genital and rectal gonorrhea; throat gonorrhea is somewhat harder to clear and requires a test-of-cure swab 1–2 weeks later. The key word is 'correctly': the wrong drug, an incomplete course, or an oral substitute won't clear the infection and drives the resistance that makes gonorrhea harder to treat for everyone.

Neisseria gonorrhoeae has developed resistance to every antibiotic class previously used against it, including oral options. Fluoroquinolones (ciprofloxacin, levofloxacin) are no longer effective. Oral cephalosporins like cefixime have inadequate drug concentrations at the throat and are no longer recommended as first-line. Azithromycin-based regimens have been discontinued due to widespread resistance. The injectable ceftriaxone achieves drug concentrations that oral drugs cannot replicate, which is exactly why the current standard requires an injection rather than a pill. If you cannot receive an injection due to a true cephalosporin allergy, ask your provider about the CDC-recommended alternative (gentamicin plus azithromycin).

In men, gonorrhea typically produces a thick, yellow or yellow-green urethral discharge: often described as purulent, and more pronounced than the thinner, clearer discharge of chlamydia. This is the symptom that earned gonorrhea the name 'the drip.' In women, discharge may be increased or changed in color or consistency, but it's frequently indistinguishable from normal vaginal secretions, or absent altogether. Rectal infection may produce a small amount of discharge, but is usually found only on examination or by swab. Never rely on discharge characteristics to diagnose or rule out gonorrhea.

Yes, pharyngeal gonorrhea is common and is one of the most clinically important sites because it is almost always completely asymptomatic. Most people with throat gonorrhea have no sore throat, no swollen glands, and nothing to suggest an infection is present. It's detected only with a throat swab (NAAT), and it's particularly prevalent among men who have sex with men who practice receptive oral sex. Pharyngeal gonorrhea is also the most difficult site to treat: cure rates with ceftriaxone are lower at the throat than at genital sites, which is why a test-of-cure swab 7–14 days after treatment is recommended.

Wait at least 1–2 weeks after a possible exposure for a reliable result. N. gonorrhoeae needs time to establish a detectable infection: a NAAT can detect it within a few days in some cases, but testing in the first 24–72 hours risks a false-negative even if infection is present. If you test early and the result is negative but you have symptoms or a confirmed exposure, re-test at the 2-week mark. For routine screening after an unprotected encounter with no symptoms, testing at 1–2 weeks is appropriate.

Yes, and this is one of the most serious reasons to test and treat early. In women, untreated gonorrhea ascends from the cervix into the uterus and fallopian tubes, causing pelvic inflammatory disease (PID). PID causes tubal scarring that can partially or fully block the fallopian tubes: preventing fertilization (infertility) or allowing a fertilized egg to implant in the tube rather than the uterus (ectopic pregnancy, which is life-threatening). Studies suggest 10–15% of untreated women develop PID, and each subsequent infection multiplies the cumulative scarring risk. In men, untreated gonorrhea can cause epididymitis, which in severe cases can impair sperm function. Early treatment with ceftriaxone prevents these outcomes entirely.

Disseminated gonococcal infection (DGI) occurs when N. gonorrhoeae enters the bloodstream and spreads beyond the original infection site: affecting joints, skin and, rarely, the heart or brain. It develops in approximately 1–3% of untreated gonorrhea cases and is the most common cause of infectious arthritis in sexually active young adults. The classic presentation is a triad: migratory polyarthritis (pain and swelling that moves from joint to joint), dermatitis (pustular or hemorrhagic skin lesions, often on the hands and feet), and tenosynovitis (tendon-sheath inflammation). DGI can progress to septic arthritis in a single joint, which can permanently destroy cartilage if not treated promptly, and to endocarditis or meningitis in rare cases. It requires hospitalization and intravenous ceftriaxone.

For uncomplicated urogenital gonorrhea treated with ceftriaxone, a routine test-of-cure is not required if symptoms resolve: but the CDC strongly recommends re-testing at 3 months, because re-infection from an untreated partner is the most common reason gonorrhea comes back. For pharyngeal (throat) gonorrhea, a test-of-cure NAAT or culture at 7–14 days after treatment IS specifically recommended, because cure rates at the throat are lower than at genital sites even with ceftriaxone. If you still have symptoms 7 or more days after treatment, that requires clinical evaluation: it may be re-infection, a treatment failure or a different diagnosis.

Yes, and it's more common than most people expect. Being cured of gonorrhea gives you no immunity whatsoever: you can be re-infected the same day if you have sex with a partner who still has untreated gonorrhea. Re-infection from an untreated partner is, in fact, the most common reason gonorrhea seems to 'come back' after a confirmed course of ceftriaxone. True antibiotic treatment failure, meaning the drug didn't clear the infection, is rare when ceftriaxone is correctly administered, but it does occur and requires culture and sensitivity testing. The distinction matters because re-infection is treated with standard ceftriaxone, while true treatment failure requires investigation and a different approach.

Absolutely yes, and this is why asymptomatic gonorrhea drives the epidemic. N. gonorrhoeae colonizes mucous membranes regardless of whether symptoms develop, and the bacteria are shed in genital secretions, rectal fluid and saliva from infected throat tissue. Most rectal and throat infections, and roughly half of all genital infections in women, produce no symptoms, yet all of them are contagious. The absence of symptoms does not reduce transmissibility. This is the fundamental reason routine screening matters: most gonorrhea is transmitted by people who have no idea they're infected.

Yes, a newborn can contract gonorrhea from an infected parent during vaginal delivery. The resulting infection is called gonococcal ophthalmia neonatorum: gonorrhea colonizes the baby's eyes as it passes through an infected birth canal, causing a rapidly progressive purulent eye infection that can cause permanent corneal scarring and blindness within days if not treated with systemic ceftriaxone. This is why all newborns in the US routinely receive antibiotic eye drops (erythromycin ointment) at birth, but prophylaxis is not 100% effective and is not a substitute for prenatal testing and treatment. Screening at the first prenatal visit (and again in the third trimester for those at risk) is the primary safeguard for the baby.

Yes, substantially. Active gonorrheal infection increases both the risk of acquiring HIV during an exposure and the risk of transmitting HIV to a partner. The mechanism is biological: gonorrhea causes mucosal inflammation that disrupts the epithelial barrier, concentrates HIV-susceptible immune cells (CD4+ T-cells) at the site of infection, and amplifies HIV viral shedding in genital secretions. Studies suggest that active gonorrhea increases the per-act probability of HIV acquisition and transmission by approximately 2–5 times. This makes STI screening and treatment, including gonorrhea, an integral component of HIV prevention, not a separate concern.

Penicillin allergy does not automatically preclude ceftriaxone, which is a cephalosporin, a related but distinct antibiotic class. True immunological cross-reactivity between penicillin and cephalosporins is estimated at less than 2% in people with documented penicillin allergy, and most people who report penicillin allergy are not actually allergic on formal testing. If your allergy history suggests a high risk of cross-reaction (anaphylaxis, urticaria or severe prior penicillin reaction), discuss this with your provider, allergy evaluation or desensitization may be appropriate. For confirmed, severe cephalosporin allergy, the CDC-recommended alternative for gonorrhea is gentamicin 240 mg IM single dose plus azithromycin 2 g orally (note: azithromycin alone is not effective for gonorrhea).

Yes, gonorrhea can be transmitted through oral sex in multiple directions. The person giving oral sex can acquire pharyngeal (throat) gonorrhea from an infected genital or rectal area. The person receiving can acquire urethral or cervical gonorrhea from an infected mouth and throat. Pharyngeal gonorrhea is especially common in men who have sex with men who practice receptive oral sex, and it is almost universally asymptomatic, most people with throat gonorrhea have no sore throat or discomfort. Because condoms and dental dams are used less consistently for oral sex than for vaginal or anal sex, oral gonorrhea transmission is a significant and underappreciated route of spread. Site-specific throat swabs are the only way to detect it.

Syphilis is almost always diagnosed with a blood test, a quick draw or finger-prick that detects antibodies produced in response to Treponema pallidum infection. Two types of tests are used: non-treponemal tests (RPR or VDRL) screen for general antibody activity and produce a titer that tracks disease activity over time; treponemal tests (TPPA, FTA-ABS or EIA) confirm that the antibodies are specific to syphilis. Both are usually done together because neither type alone tells the whole story. If you have an active sore, a clinician can also swab it for direct microscopy or PCR, which detects the bacteria before the antibody tests become reactive.

The primary syphilis sore, called a chancre, is typically a single, firm, round ulcer with clean, raised edges and a smooth base. What makes it so deceptive is that it is almost always painless: no tenderness, no discharge, no bleeding. It appears at the site where T. pallidum entered the body, usually on the genitals, anus, lips or throat, and it often hides inside the vagina, rectum or throat where you can't see or feel it. The sore heals on its own in 3–6 weeks, which people routinely interpret as recovery, but the bacteria have simply moved deeper. If you notice a painless ulcer anywhere on your genitals or mouth, get a blood test immediately rather than waiting to see if it resolves.

Blood tests for syphilis, both RPR and treponemal tests, become detectable 1–4 weeks after the chancre appears, which is roughly 3–6 weeks after the sexual exposure that caused it. For the most reliable negative result, test at least 6 weeks after a potential exposure. If you test earlier and get a negative result but you have a sore, know you were exposed, or have symptoms of secondary syphilis, retest at 6 weeks and again at 3 months. A single early negative is not a green light. If you have an active sore, a clinician can swab it for direct testing even before the blood test turns positive.

Yes: syphilis is completely curable with penicillin, which has been the treatment of choice for over 70 years with zero documented resistance. Primary, secondary and early latent syphilis (under one year) requires a single intramuscular injection of benzathine penicillin G. Late latent or unknown-duration syphilis requires three weekly injections. Neurosyphilis requires intravenous penicillin G given in a hospital or infusion setting for 10–14 days. The critical limitation: penicillin cures the infection and stops further damage, but it cannot reverse damage already done. Neurosyphilis that has caused dementia, aortic disease that has caused an aneurysm, or congenital infection that has caused deafness are not reversed by treatment. Getting tested and treated early is what prevents those outcomes.

RPR (Rapid Plasma Reagin) is a non-treponemal test that detects antibodies produced during syphilis infection but not specifically targeted at Treponema pallidum. It is fast, inexpensive and quantitative, the titer (e.g., 1:32) reflects disease activity and falls with successful treatment, making it ideal for monitoring cure. TPPA (Treponema pallidum Particle Agglutination Assay) is a treponemal test that detects antibodies specifically targeting T. pallidum proteins. It is more specific, far fewer false positives, but it remains reactive for life even after successful treatment, so it cannot be used to assess whether treatment worked. In practice: RPR screens and monitors; TPPA confirms and diagnoses. Most labs now use a reverse-sequence algorithm: automated treponemal EIA first, then RPR if positive.

This is one of the most common points of confusion about syphilis testing. Treponemal tests, TPPA, FTA-ABS, EIA, remain reactive for life after successful treatment. They detect antibodies specific to Treponema pallidum that the immune system produces and retains permanently, even after the bacteria are gone. A positive treponemal test in someone who was previously treated and cured does not indicate active infection or treatment failure. The test you need to distinguish past-cured infection from active infection is the RPR (or VDRL): after successful treatment, the RPR titer falls and eventually becomes non-reactive (or stays at a low, stable level called a "serofast" state). If your RPR is negative or at a stable low titer and you have no symptoms, you are almost certainly cured. If the RPR is rising, that indicates active infection requiring treatment.

Yes: latent syphilis, which has no symptoms at all, is one of the most dangerous states to be in precisely because it is silent. The bacteria are not dormant in the sense of being inactive; T. pallidum persists in tissues throughout the body and, in 25–30% of untreated people, drives the development of tertiary disease years to decades later. Tertiary syphilis includes neurosyphilis (progressive dementia, loss of coordination), cardiovascular disease (aortic aneurysm, heart failure) and gummatous disease (destructive granulomas in skin, bone and organs). By the time those complications become symptomatic, significant irreversible damage has already occurred. The latent stage is also the time when a pregnant person can transmit the infection to a fetus. Feeling fine is not the same as being fine, a blood test is the only way to know.

The Jarisch-Herxheimer reaction is a predictable side effect of syphilis treatment that is often confused with a penicillin allergy, they are completely different things. It occurs when penicillin kills large numbers of Treponema pallidum rapidly, releasing bacterial antigens that trigger a systemic inflammatory response. Within 2–8 hours of the first treatment dose, you may develop fever (sometimes high), rigors, headache, muscle aches, sweating and a temporary flare of the syphilis rash. It typically peaks at about 8 hours and resolves within 24 hours. Manage it with acetaminophen and rest, and stay hydrated. It is more pronounced with primary and secondary syphilis than with latent disease. In pregnancy, the fever can trigger uterine contractions and fetal distress, which is why treatment in pregnant patients is given in a monitored setting. Experiencing this reaction does not mean penicillin is harming you, it means the treatment is working.

Treponema pallidum crosses the placenta readily and can infect the fetus at any point during pregnancy, though transmission is most efficient, approaching 80%, with untreated primary or secondary maternal syphilis in the first or early second trimester. The results are severe: miscarriage, stillbirth, premature birth, and in liveborn infants, a constellation of findings called congenital syphilis including nasal discharge, widespread rash, hepatosplenomegaly, severe anemia, bone lesions and, appearing years later, Hutchinson teeth, corneal scarring and hearing loss. In 2023, 3,882 U.S. newborns were diagnosed with congenital syphilis and 279 died. Every one of those outcomes is preventable: a blood test at the first prenatal visit and a penicillin injection stops transmission to the baby. If you are pregnant and have not been tested for syphilis, get tested today.

Yes. Syphilis is transmitted by direct contact with a sore: and chancres can form on the lips, tongue, throat and tonsils as readily as they form on genitalia. Performing oral sex on a partner who has a genital sore, or receiving oral sex from a partner who has an oral sore, both transmit syphilis. The oral chancre is often smaller and less visible than a genital one, and it is painless, so people with oral syphilis frequently don't know they have it. If your testing includes a throat swab for gonorrhea or chlamydia, it does not test for syphilis, you need a blood test specifically for syphilis.

The relationship between syphilis and HIV runs in both directions. An open syphilis sore substantially increases both the acquisition and transmission risk for HIV, the disrupted epithelium and local inflammation at a chancre are a direct entry point for HIV. Conversely, in people who already have HIV, syphilis is more likely to cause unusual or accelerated manifestations: neurosyphilis and ocular syphilis occur more commonly and can appear earlier in the disease course than in HIV-negative individuals. Treatment for syphilis in people with HIV is generally the same as standard CDC regimens, but follow-up monitoring is more intensive because treatment response may be slower. People with HIV and syphilis coinfection should have careful clinical and serological follow-up at 3, 6, 9, 12 and 24 months.

Neurosyphilis is invasion of the central nervous system by Treponema pallidum, and it can happen at any stage of syphilis, it is not exclusively a late or tertiary complication. Early neurosyphilis presents as aseptic meningitis: severe headache, stiff neck, fever and cranial nerve involvement (facial weakness, double vision, hearing loss). Late neurosyphilis, developing after years of untreated infection, produces two classic syndromes: general paresis, a progressive dementia with personality change and psychiatric symptoms; and tabes dorsalis, a degeneration of the posterior spinal cord causing stabbing leg pains, loss of position sense and an unsteady gait. Ocular syphilis (uveitis, retinitis, optic neuritis) is classified as neurosyphilis for treatment purposes and can cause permanent blindness. Neurosyphilis is diagnosed by examining spinal fluid (lumbar puncture) and is treated with high-dose IV penicillin G for 10–14 days, a single IM injection is not adequate.

Yes: and this matters clinically, not just ethically. Partners who were exposed during your infectious period need to be tested and potentially treated, since they may have syphilis without knowing it and may be passing it on or developing complications. For primary syphilis, notify partners from the 3 months before your symptom onset; for secondary syphilis, 6 months; for early latent, 1 year. You can tell partners yourself, or your local health department's disease intervention specialist (DIS) can notify partners confidentially without revealing your name. Many areas also have online partner notification services. Avoiding sex with current partners until treatment is complete and the chancre has healed prevents re-infection.

The same infection cannot come back after successful treatment, penicillin permanently clears the bacteria. But syphilis confers no lasting immunity, so you can be re-infected from a new or untreated partner as easily as if you had never had it. Re-infection is common, particularly in communities with high syphilis rates and among people with multiple partners. Clinically, re-infection looks identical to a new infection: a rising RPR titer, often with symptoms, even in someone who was treated and confirmed cured. This is why follow-up blood testing at 6, 12 and 24 months matters: a rising titer indicates re-infection (or less commonly, treatment failure) and requires a new course of treatment.

The contagiousness of syphilis depends heavily on the stage. Primary syphilis, when active chancres are present, is highly contagious through sexual contact with those sores. Secondary syphilis, with its disseminated rash, condylomata lata and mucous patches, is also highly contagious; the condylomata lata in skin folds are particularly infectious because they are moist and teeming with spirochetes. Early latent syphilis (less than one year since infection) carries a risk of sexual transmission and also a risk of relapse to secondary symptoms. Late latent syphilis (more than one year) is not considered sexually transmissible. Tertiary syphilis is not contagious. Critically, a pregnant person with any stage of syphilis can transmit it to the fetus, including late latent. After a single IM penicillin injection, the risk of sexual transmission drops rapidly, but avoid sex until the treatment is complete and the sore has healed.

For people with a cervix, HPV testing is done on a cervical sample: collected by a clinician during a pelvic exam or, increasingly, via self-collection devices. The standard schedule: Pap test every 3 years starting at age 21; primary HPV test or Pap + HPV co-test every 5 years from age 30 (ASCCP supports primary HPV testing from age 25). These are cancer-prevention screening tests: they tell you whether high-risk HPV is currently present in cervical cells, not whether you were recently exposed. For men, no routine HPV test exists, the primary protective action is vaccination. If you notice genital warts, see a clinician for a same-visit visual diagnosis; no lab test is required.

There is no post-exposure window-period test for HPV the way there is for chlamydia, gonorrhea, or HIV. An HPV test on a cervical sample doesn't diagnose a recent exposure, it detects persistent high-risk HPV in cervical cells over time. For people with a cervix, the right response to a potential HPV exposure is staying on your routine cervical screening schedule (Pap every 3 years from age 21; HPV test or co-test every 5 years from age 30) rather than seeking a one-time post-exposure test. Genital warts, caused by low-risk types, typically appear 2–3 months after exposure but can take up to a year or more to develop.

The HPV infection itself has no antiviral treatment: but about 90% of infections clear on their own as the immune system suppresses the virus, typically within 1–2 years. What clinicians can treat are the conditions HPV causes: genital warts (removed with topical medications or in-office procedures) and precancerous cervical changes (LEEP or cone biopsy). Treating precancerous lesions is highly effective and prevents cervical cancer from developing. Vaccination prevents future infections with covered types, it doesn't treat existing infections but does protect against types not yet acquired.

Gardasil 9 is routinely recommended at age 11–12 (starting as early as 9), with catch-up vaccination through age 26. Adults 27–45 may benefit through a shared clinical decision based on risk factors and prior exposure. The vaccine is most effective before any HPV exposure, but it is not pointless after sexual debut, it still protects against the nine covered types you haven't yet acquired. Studies show benefit even in people with prior HPV exposure. The vaccine is very safe with mild, brief side effects (sore arm, occasional low-grade fever). Given that HPV causes most cervical cancers and a growing fraction of oropharyngeal cancers, Gardasil 9 is one of the most effective cancer-prevention tools ever developed.

Persistent infection with high-risk HPV types, especially 16 and 18, disrupts normal cell-cycle regulation, causing precancerous changes (e.g., CIN 2/3 in the cervix) that can progress to invasive cancer over 10–20 years if undetected and untreated. This progression is slow enough that it can be interrupted at multiple points: (1) Gardasil 9 vaccination prevents the highest-risk types from ever establishing infection; (2) regular cervical screening detects precancerous changes when they are 100% treatable by LEEP or cone biopsy; (3) treating detected precancer prevents cancer from developing. The system works, countries with high vaccination and screening rates are seeing dramatic declines in cervical cancer incidence.

Genital warts appear as soft, flesh-colored, gray, or pink bumps, sometimes flat, sometimes raised, or cauliflower-shaped, on or around the genitals, anus, or groin. They are caused by low-risk HPV types 6 and 11, which are entirely separate from the high-risk cancer-causing types. Having genital warts does NOT mean you have a cancer-causing HPV type, though it is biologically possible to carry both simultaneously. Warts are diagnosed by visual examination on the same clinical visit; treatment options include topical prescription creams (imiquimod, podofilox) or in-office removal (cryotherapy, TCA, excision). Warts recur in 20–50% of cases because the virus persists in surrounding tissue.

No routine FDA-approved HPV test exists for men. There is no blood test, urine test, or swab-based HPV screen for people with a penis. For men at higher risk of anal cancer, particularly MSM and people with HIV, some specialized clinics offer anal Pap tests (anal cytology) followed by high-resolution anoscopy if abnormal results are found, but this is not a universal recommendation. The most important protective action for men is HPV vaccination (Gardasil 9) before potential exposure. Men should also watch for visible genital warts and seek clinical evaluation if any appear.

Self-collection devices for cervical HPV/Pap testing are now available at some clinics and through selected at-home kits, you self-insert a swab and mail it to a CLIA-certified lab. These are specifically designed for high-risk HPV screening in people with a cervix, typically for those age 25 or older per ASCCP guidance. They are not a general exposure test and do not test for low-risk HPV types that cause genital warts. No at-home HPV test exists for men or people with penises.

HPV is so common, ~80% of sexually active people acquire it, that there is no clinical partner-notification protocol the way there is for chlamydia or syphilis. Because no test exists for men and most infections are transient, the calculus is different from bacterial STIs. That said, sharing what you know with a partner, especially if you have active warts or a recent abnormal cervical result, supports informed decision-making. The most actionable step for any partner is HPV vaccination. Partners with a cervix should also stay current on their cervical screening schedule.

For most pregnant people with HPV, the infection does not affect the pregnancy or the developing baby. Genital warts may grow faster during pregnancy due to hormonal and immune changes; imiquimod, podofilox, and sinecatechins are contraindicated: a clinician will advise on safe alternatives (TCA, cryotherapy, excision). Cervical precancer detected during pregnancy is typically managed conservatively, with definitive treatment deferred until after delivery unless invasive cancer is a concern. In rare cases, HPV types 6 and 11 can pass to a newborn during delivery and cause recurrent respiratory papillomatosis in the child's airway, another compelling reason for vaccination before pregnancy.

Yes. Clearing an infection with one HPV type provides no meaningful protection against the 200+ other HPV types, including other oncogenic types. Having been infected with HPV 16, for example, does not protect against HPV 18, 31, 33, or others. Gardasil 9 covers nine types, but sexual exposure can still involve types not covered by the vaccine. This is why vaccination before first sexual exposure (ideally covering as many types as possible before any exposure), combined with ongoing condom use and cervical screening, remains important even for people who have previously had HPV.

Yes. HPV, primarily type 16, now causes approximately 70% of oropharyngeal cancers (base of tongue, tonsils, posterior pharynx) in the United States, and this fraction has been rising for decades as tobacco-related cancers declined. HPV-related throat cancers are more common in men and often present at a more advanced stage because there is no routine screening test equivalent to the cervical Pap smear. Protection against HPV-related oropharyngeal cancer relies primarily on vaccination (Gardasil 9 covers HPV 16) and, to a lesser degree, using dental dams or condoms during oral sex, though these provide incomplete protection. There is currently no approved screening test or surveillance program for oropharyngeal HPV.

No, different HPV types cause warts at different body sites. Common hand warts and plantar warts (on the soles of the feet) are caused by low-risk non-genital HPV types (such as 1, 2, and 4), spread by non-sexual skin contact. The types that cause genital warts (HPV 6 and 11) and cancer-causing genital HPV types (16, 18, and others) are distinct from the ones responsible for hand and foot warts. Gardasil 9 does not protect against the HPV types that cause common hand or plantar warts. Over-the-counter wart removers designed for hand and foot warts, especially those with salicylic acid or freezing agents, are not safe for use on genital skin and should never be applied there.